Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue

Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has mat...

Full description

Saved in:
Bibliographic Details
Published inCPT: pharmacometrics and systems pharmacology Vol. 4; no. 9; pp. 495 - 497
Main Authors Stroh, M, Carlile, DJ, Li, C‐C, Wagg, J, Ribba, B, Ramanujan, S, Jin, J, Xu, J, Charoin, J‐E, Xhu, Z‐X, Morcos, PN, Davis, JD, Phipps, A
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.09.2015
John Wiley & Sons, Ltd
Subjects
Biomarkers
Cancer therapies
Chemotherapy
Drug dosages
Immune system
Immunotherapy
Melanoma
Stockholders
Online AccessGet full text

Cover

More Information
Summary:Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has matured during this time, application to CIT may not be straightforward since CIT acts via the immune system. Here we discuss where qCP approaches might best borrow or start anew for CIT.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2163-8306
2163-8306
DOI:10.1002/psp4.12014